# California Court Dismisses Pharma Kickback Suit

A federal judge dismissed without prejudice a False Claims Act lawsuit alleging kickback schemes involving Genentech, Novartis Pharmaceuticals, Regeneron, and others. The court based the dismissal on the whistleblower’s failure to serve the complaint by the September 16 deadline; it did not resolve the allegations on their merits. The case creates no new contract award or procurement opportunity, but highlights litigation and compliance exposure for pharmaceutical companies participating in federal healthcare programs.

- Pharmaceutical contractors and suppliers to federal healthcare programs can use the case as a reminder to assess their exposure to False Claims Act and kickback allegations.
- The dismissal was procedural and without prejudice, so it should not be treated as a ruling that the alleged conduct did or did not occur.
- No contract value, solicitation, or procurement action was identified in the signal.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** October 21, 2026

### Government Entities
- U.S. District Court for the Central District of California

### Vendors
- Genentech Inc. (Defendant in False Claims Act litigation)
- Novartis Pharmaceuticals Corp. (Defendant in False Claims Act litigation)
- Regeneron Pharmaceuticals Inc. (Defendant in False Claims Act litigation)